Yates Nicole L, Liao Hua-Xin, Fong Youyi, deCamp Allan, Vandergrift Nathan A, Williams William T, Alam S Munir, Ferrari Guido, Yang Zhi-yong, Seaton Kelly E, Berman Phillip W, Alpert Michael D, Evans David T, O'Connell Robert J, Francis Donald, Sinangil Faruk, Lee Carter, Nitayaphan Sorachai, Rerks-Ngarm Supachai, Kaewkungwal Jaranit, Pitisuttithum Punnee, Tartaglia James, Pinter Abraham, Zolla-Pazner Susan, Gilbert Peter B, Nabel Gary J, Michael Nelson L, Kim Jerome H, Montefiori David C, Haynes Barton F, Tomaras Georgia D
Duke Human Vaccine Institute, Durham, NC 27710, USA.
Sci Transl Med. 2014 Mar 19;6(228):228ra39. doi: 10.1126/scitranslmed.3007730.
HIV-1-specific immunoglobulin G (IgG) subclass antibodies bind to distinct cellular Fc receptors. Antibodies of the same epitope specificity but of a different subclass therefore can have different antibody effector functions. The study of IgG subclass profiles between different vaccine regimens used in clinical trials with divergent efficacy outcomes can provide information on the quality of the vaccine-induced B cell response. We show that HIV-1-specific IgG3 distinguished two HIV-1 vaccine efficacy studies (RV144 and VAX003 clinical trials) and correlated with decreased risk of HIV-1 infection in a blinded follow-up case-control study with the RV144 vaccine. HIV-1-specific IgG3 responses were not long-lived, which was consistent with the waning efficacy of the RV144 vaccine. These data suggest that specific vaccine-induced HIV-1 IgG3 should be tested in future studies of immune correlates in HIV-1 vaccine efficacy trials.
HIV-1特异性免疫球蛋白G（IgG）亚类抗体可与不同的细胞Fc受体结合。因此，具有相同表位特异性但亚类不同的抗体可具有不同的抗体效应功能。对具有不同疗效结果的临床试验中使用的不同疫苗方案之间的IgG亚类谱进行研究，可为疫苗诱导的B细胞反应质量提供信息。我们发现，HIV-1特异性IgG3区分了两项HIV-1疫苗疗效研究（RV144和VAX003临床试验），并且在一项对RV144疫苗进行的盲法随访病例对照研究中，与HIV-1感染风险降低相关。HIV-1特异性IgG3反应并非长期存在，这与RV144疫苗效力的减弱一致。这些数据表明，在未来HIV-1疫苗疗效试验的免疫相关性研究中应检测特定疫苗诱导的HIV-1 IgG3。
